Old Mission Investment Co LLC Takes $764,000 Position in Stryker Corporation $SYK

Old Mission Investment Co LLC purchased a new position in Stryker Corporation (NYSE:SYK) in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 2,419 shares of the medical technology company’s stock, valued at approximately $764,000.

Several other institutional investors have also made changes to their positions in SYK. Rakuten Investment Management Inc. acquired a new position in shares of Stryker in the second quarter worth $18,646,000. Swedbank AB boosted its position in Stryker by 6.6% during the fourth quarter. Swedbank AB now owns 129,027 shares of the medical technology company’s stock valued at $45,349,000 after purchasing an additional 7,934 shares during the last quarter. Crossmark Global Holdings Inc. grew its stake in Stryker by 31.1% in the fourth quarter. Crossmark Global Holdings Inc. now owns 26,820 shares of the medical technology company’s stock valued at $9,426,000 after purchasing an additional 6,367 shares in the last quarter. Royal Bank of Canada grew its stake in Stryker by 6.5% in the first quarter. Royal Bank of Canada now owns 3,273,232 shares of the medical technology company’s stock valued at $1,075,552,000 after purchasing an additional 199,863 shares in the last quarter. Finally, Rathbones Group PLC increased its position in Stryker by 647.9% in the 4th quarter. Rathbones Group PLC now owns 219,265 shares of the medical technology company’s stock worth $77,065,000 after purchasing an additional 189,948 shares during the last quarter. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Stryker

In related news, insider Debra King sold 826 shares of the company’s stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $336.30, for a total transaction of $277,783.80. Following the completion of the sale, the insider directly owned 6,210 shares of the company’s stock, valued at approximately $2,088,423. This represents a 11.74% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Ronda Stryker sold 50,000 shares of the firm’s stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $340.10, for a total transaction of $17,005,000.00. Following the completion of the transaction, the director owned 2,251,375 shares in the company, valued at $765,692,637.50. The trade was a 2.17% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 351,267 shares of company stock worth $118,197,701. 4.60% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on SYK. JPMorgan Chase & Co. cut their price target on Stryker from $400.00 to $350.00 and set an “overweight” rating for the company in a research note on Friday, July 31st. Argus set a $370.00 price objective on Stryker in a report on Thursday, July 9th. Citizens Jmp cut their price objective on shares of Stryker from $440.00 to $400.00 and set a “market outperform” rating on the stock in a research report on Monday, August 3rd. Truist Financial raised their price objective on shares of Stryker from $330.00 to $340.00 and gave the company a “hold” rating in a research report on Friday, July 31st. Finally, BMO Capital Markets assumed coverage on shares of Stryker in a research report on Wednesday, July 8th. They issued an “outperform” rating and a $369.00 target price for the company. One research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have issued a Hold rating to the company. According to MarketBeat.com, Stryker currently has a consensus rating of “Moderate Buy” and a consensus target price of $386.28.

Stryker Price Performance

Shares of NYSE:SYK opened at $302.92 on Friday. The stock has a market capitalization of $116.19 billion, a P/E ratio of 31.39, a P/E/G ratio of 1.93 and a beta of 0.76. The business has a 50-day moving average of $328.84 and a two-hundred day moving average of $329.73. Stryker Corporation has a fifty-two week low of $281.00 and a fifty-two week high of $396.37. The company has a debt-to-equity ratio of 0.59, a current ratio of 2.16 and a quick ratio of 1.33.

Stryker (NYSE:SYK) last issued its quarterly earnings data on Thursday, July 30th. The medical technology company reported $3.69 earnings per share for the quarter, beating analysts’ consensus estimates of $3.49 by $0.20. Stryker had a return on equity of 23.63% and a net margin of 14.43%.The business had revenue of $6.59 billion for the quarter, compared to the consensus estimate of $6.58 billion. During the same period last year, the business earned $3.13 EPS. The firm’s revenue was up 9.4% compared to the same quarter last year. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. On average, equities research analysts predict that Stryker Corporation will post 15.03 EPS for the current fiscal year.

Stryker Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be given a $0.88 dividend. The ex-dividend date of this dividend is Wednesday, September 30th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.2%. Stryker’s dividend payout ratio (DPR) is currently 36.48%.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.